Larvol Delta - BioThera-Solutions-Announces-the-First-Patient-Dosed-in-Phase-III-Clinical-Trial-for-BAT2206-a-Proposed-Biosimilar-of-Stelara-Ustekinumab

BAT2206 (ustekinumab biosimilar) - Bio-Thera Solutions

https://www.businesswire.com/news/home/20210715005583/en/Bio-Thera-Solutions-Announces-the-First-Patient-Dosed-in-Phase-III-Clinical-Trial-for-BAT2206-a-Proposed-Biosimilar-of-Stelara%C2%AE-Ustekinumab

Jul 15, 2021

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next